Moderate growth at Bristol-Myers Squibb and Amgen moved the two companies into the top 10 pharma ranks, based on the most recent Scrip 100 rankings, while declining growth at Gilead and Teva moved those drug makers out.
In 2018, the top 100 publicly listed and reportable medical device technology companies had global sales spanning from over $30bn to some $100m in the lower reaches. As the latest In Vivo Medtech 100 ranking shows, many of the major changes in value sales were linked to company restructurings. But there were some impressive organic gains too.
The Scrip 100 universe gathers FY2018 financial performance data and compares the activities of the Top 100 biopharma businesses, ranked by pharma sales.
The full Scrip 100 data set for 2020 is now available and includes data on R&D spending, total revenues, employee numbers and sales for the top 100 biopharmaceutical companies (based on FY 2018).
If you are a subscriber, click here to download the data in Excel format.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.